Navigation Links
Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013

THE WOODLANDS, Texas, Feb. 18, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, will release its fourth quarter and year end 2012 financial results on Thursday, February 21, 2013 before the financial markets open.  Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2012 at 11:00 a.m. Eastern Time on February 21, 2013. 

The dial-in number for the conference call is 888-645-5875 (within the US/Canada) or 970-300-1531 (international).  The conference ID for all callers is 12316846.  Investors can access a live webcast of the call at  An archived version of the webcast will be available on the website through March 21, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
3. Research and Markets: Cell Therapy - Technologies, Markets and Companies - 2013 Report
4. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at
10. The Employment Report for February, 2013: Health Care Sector Stimulates Job Growth Throughout the Recession
11. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
Post Your Comments:
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant ... officially launched and multiple surgeries have been completed with this new posterior thoracolumbar ... Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal System pioneers ...
(Date:10/9/2015)... , Oct. 9, 2015 On October ... the Congressional Record her statement recognizing the third annual ... 11-17. IPAW is sponsored by the Plasma Protein ... is designed to:   , Raise global awareness ... plasma donors in saving and improving lives , ...
(Date:10/9/2015)... 2015  DePuy Synthes Trauma* announced today the U.S. ... Technology**, the only pre-hydrated demineralized cancellous bone tissue ... and ankle, hand and wrist), including fusion, and for ... the 2015 Orthopaedic Trauma Association (OTA) Annual Meeting. ... new bone growth) and osteoinductive 2,3 (stimulates new ...
(Date:10/9/2015)... San Francisco, CA (PRWEB) , ... October 09, 2015 , ... ... with a study that aims to better understand the relationship between weight management and ... more frequently and more accurately from participants using an iPhone app. , The uBiome ...
Breaking Biology Technology:
(Date:10/9/2015)... Oct. 09 2015 ... of the "Samsung Galaxy S6 Fingerprint ... to their offering. --> ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> Research and Markets ...
(Date:10/7/2015)... --> --> According to ... quarter 2015 amounted to around 960 MSEK. This exceeds the ... communicated 20 August 2015. --> ... continued growing demand for the company,s products, the revenues for ... during the third quarter. The revenue guidance for 2015 is ...
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
Breaking Biology News(10 mins):